Skip to main content
White Paper

How to Meet the FDA Diversity Action Plan Guidance

The pending FDA Guideline’s intention is clear—pharma companies must plan, report and collaborate to improve diverse representation in clinical trials. Most sponsors have assessed their capability and are gearing up for action. However, “Analysis by Paralysis” or even “Trial and Error,” should not stand in the way of progress. 

For most companies, transformation is needed, but a single, one-size fits all solution might not be the answer to improving diversity in research. Flexible and interactive strategies must be implemented to drive a solution that delivers results. In this whitepaper, Science 37 Diversity and Inclusion leaders share tips and strategies on how to achieve diversity in clinical trials. 

Learn how to:

  • Make diversity part of your culture
  • Engage clinical trial participants as customers 
  • Continuously monitor for patient experience—while improving and adapting
  • And how leveraging decentralized clinical trials can improve patient access and reach. 

Fill out the form now to access these insights.